The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Healthy Humans.
NCT ID: NCT00345215
Last Updated: 2011-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
26 participants
INTERVENTIONAL
2006-05-31
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Essential Hypertension
NCT00345124
Blood Pressure and Diurnal Variation in Sodium, Potassium, and Water Excretion
NCT00005204
The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Hypertensive Versus Healthy Subjects
NCT02527837
Adverse Neurogenic Actions of Dietary Salt
NCT02881515
Food and Salt Handling in Diuresis
NCT04526340
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High Sodium Diet
250-350 mmol
Low Sodium Diet
25-35 mmol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-65 years
* Body mass index less or equal to 30 Kg/m2
Exclusion Criteria
* History or clinical signs of heart, brain, lung, kidney, malignant or endocrine organ disease.
* Abnormal biochemical screening of the blood regarding: red and white cell count, B-hemoglobin, P-sodium, P-potassium, P-creatinine, P-albumine, P- bilirubin, P-alanine aminotransferase, P- alkaline phosphatase, p-cholesterol and B-glucose.
* Abnormal screening of the urine regarding: blood, albumine and glucose.
* Alcohol or drug abuse
* Drug use except oral contraceptives
* Smoking
* Abnormal electrocardiogram
* Blood donation within one month of the first examination day
* Pregnancy
* Unwillingness to participate
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regional Hospital Holstebro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Medical Research, Holstebro Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erling B. Pedersen, Professor
Role: STUDY_CHAIR
Department of Medical Research, Holstebro Hospital, Denmark
Carolina C. Graffe, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Medical Research, Holstebro Hospital, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medical Research, Holstebro Hospital
Holstebro, Holstebro, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
med.res.hos.2006.cc.01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.